Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...
A new CRISPR breakthrough shows scientists can turn genes back on without cutting DNA, by removing chemical tags that act ...
Infection with the pathogenic yeast fungus Candida auris (C. auris) can wreak havoc on the health of hospital patients and ...
CRISPR Therapeutics' stock is down 19% since December, with a slow Casgevy launch and significant R&D investments, yet strong cash reserves provide a safety net. Q4 earnings show no revenue from ...
Megan Molteni reports on discoveries from the frontiers of genomic medicine, neuroscience, and reproductive tech. She joined STAT in 2021 after covering health and science at WIRED. You can reach ...
CRISPR has the power to correct genetic mutations, but current delivery methods are either unsafe or inefficient, keeping the technology from reaching its full medical potential. With the power to ...
CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...
Editor’s Note: Elizabeth Yuko, Ph.D., is a bioethicist and writer whose work has appeared in The New York Times, Rolling Stone, The Washington Post, The Atlantic and elsewhere. She is also an adjunct ...
CRISPR will get easier and easier to administer. What does that mean for the future of our species? In 2016, I attended a large meeting of journalists in Washington, DC. The keynote speaker was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback